Evidence map›Paper›PMID 28938960›Full record

ArticleAmerican heart journal2017

Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.

Oluwaseun E Fashanu, Faye L Norby, David Aguilar, Christie M Ballantyne, Ron C Hoogeveen, Lin Y Chen, Elsayed Z Soliman, Alvaro Alonso, Aaron R Folsom

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Atrial Fibrillation in Elite Athletes: A Comprehensive Review of the Literature.Journal of cardiovascular development and disease · 2024
    Review
  5. Evaluation of Galectin-3 in Dogs with Atrial Fibrillation.Animals : an open access journal from MDPI · 2024
    Article
  6. Article
  7. Impact of ABO blood type on the risk of atrial fibrillation recurrence after catheter ablation.American heart journal plus : cardiology research and practice · 2024
    Article
  8. Article
  9. The role of galectin-3 in atrial fibrillation.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Oluwaseun E FashanuDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.
Faye L NorbyDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN.
David AguilarDepartment of Medicine, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX.
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX.
Ron C HoogeveenDepartment of Medicine, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, TX.
Lin Y ChenCardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN.
Elsayed Z SolimanEpidemiological Cardiology Research Center, Wake Forest School of Medicine, Winston Salem, NC.
Alvaro AlonsoDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Aaron R FolsomDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN. Electronic address: folso001@umn.edu.
University of Minnesota · USBaylor College of Medicine · USEmory University · USWake Forest University · US

Funding

American Heart Association-American Stroke Association 16EIA26410001NHLBI NIH HHS HHSN268201100005CNHLBI NIH HHS HHSN268201100006CNHLBI NIH HHS HHSN268201100007CNHLBI NIH HHS HHSN268201100008CNHLBI NIH HHS HHSN268201100009CNHLBI NIH HHS HHSN268201100010CNHLBI NIH HHS HHSN268201100011CNHLBI NIH HHS HHSN268201100012C
6 · The paper itself

Abstract

backgroundGalectin-3, a β-galactoside binding lectin involved in important regulatory roles in adhesion, inflammation, immunity, and fibrosis, may be relevant to atrial fibrillation (AF) etiology.

methodsWe included 8,436 participants free of AF at baseline (1996-1998) and with measures of plasma galectin-3 from the Atherosclerosis Risk in Communities study. We ascertained incident AF through 2013 from study visit electrocardiograms, hospitalizations, and death certificates. Multivariable Cox proportional hazards models, adjusted for AF risk factors plus incident heart failure (HF) and coronary heart disease (CHD), were used to estimate hazard ratios for the association between galectin-3 and incident AF.

resultsThe mean age (SD) of participants was 62.6 (5.6) years, and the sample was comprised of 58.7% women and 21.2% blacks. During a median follow-up of 15.7 years, 1,185 incident cases of AF were observed. After adjusting for AF risk factors, participants with galectin-3 levels ≥90th percentile (19.5 ng/mL) had a significantly higher risk of incident AF when compared with the lowest quartile (4.4-11.9 ng/mL), with hazard ratios (95% CI) of 1.40 (1.04-1.89) for the 90th-<95th percentile and 1.51 (1.11-2.06) for the 95th-100th percentile. This association was attenuated and no longer statistically significant after accounting for incident CHD and HF as time-dependent variables.

conclusionsElevated plasma galectin-3 is associated with increased risk of incident AF. Galectin-3 may increase AF risk via pathways involving CHD and HF.

Indexed as

AtherosclerosisAtrial FibrillationBiomarkersElectrocardiographyFemaleGalectin 3HumansIncidenceMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsUnited StatesBiomarkersGalectin 3

Identifiers

PMID28938960
PMCPMC5673118
OpenAlexW2730187323

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.